Real-world results of ibrutinib in relapsed/refractory CLL in France: Early results on a large series of 428 patients

Loic Ysebaert (1) , Thérèse Aurran-Schleinitz (2) , Caroline Dartigeas (3) , Marie-Sarah Dilhuydy (4) , Pierre Feugier (5) , Anne-Sophie Michallet (6) , Olivier Tournilhac (7) , Jehan Dupuis (8) , Pierre Sinet , Claire Albrecht , Florence Cymbalista (9)

1 IUCT Oncopole - UMR 1037 - Institut Universitaire du Cancer de Toulouse - Oncopole
2 Département d'Hématologie
3 N2Cox - Niche, Nutrition, Cancer et métabolisme oxydatif
4 Service des maladies du sang
5 CHRU Nancy - Centre Hospitalier Régional Universitaire de Nancy
6 Service d'Hématologie
7 CHELTER - Role of intra-Clonal Heterogeneity and Leukemic environment in ThErapy Resistance of chronic leukemias
8 Service d'hématologie clinique
9 ASIH - Adaptateurs de signalisation en hématologie

Domaines: Hématologie

Loic Ysebaert, Thérèse Aurran-Schleinitz, Caroline Dartigeas, Marie-Sarah Dilhuydy, Pierre Feugier, et al.. Real-world results of ibrutinib in relapsed/refractory CLL in France: Early results on a large series of 428 patients. American Journal of Hematology, 2017, 92 (8), pp.E166 - E168. ⟨10.1002/ajh.24773⟩. ⟨hal-01655976⟩